A Unique Way to Force Cancer Stem Cells to Become Benign May Position this Little-Known Biotech Company for BLUE-SKY Gains.

Propanc Biopharma, Inc. (OTC: PPCB) Offers New Hope to Cancer Patients and Their Caregivers with an Innovative Technology Based on Pancreatic Enzyme Therapy!

Download Research Report

Learn More about Propanc Biopharma, Inc. by gaining access to the latest research report

    Thanks for subscribing!
    Check your email for a confirmation message.

    How does PPCB’s approach stand out in biotech’s scramble to fight cancer?

    By halting cancer cells’ ability to invade and metastasize! It has the potential to FORCE cancer stem cells to become BENIGN!

    The company’s approach addresses a global, unmet medical need of tumor recurrence and metastasis from solid tumors. The Global Metastatic Cancer Treatment Market is estimated to reach $111B by 2027.

    Key Highlights:

    • $23M has been raised since the company’s inception.
    • 40 years combined pharma/biotech experience.
    • 80 years of combined scientific research expertise.
    • 76 patents either in force or pending.
    • Lead candidate PRP has the potential to convert cancerous cells back into normal cells.

    PPCB is leading a new frontier in cancer treatment and may not remain under the radar much longer!

    The global oncology landscape continues to evolve. There are ongoing efforts to discover, develop, and provide innovative treatments aimed at improving outcomes for a growing number of cancer patients. 

    The biotech arena was recently boosted by the announcement of AbbVie buying Immunogen, a maker of targeted cancer drugs, for a staggering $10 billion. Cancer is a big business and big pharma is paying big money to stay ahead.

    According to Fortune Business Insights’ findings, the global market for oncology drugs reached a value of $184.95 billion in 2022. Projections indicate significant growth, with the market expected to increase from $205.52 billion in 2023 to an estimated $484.32 billion by 2030, representing a compound annual growth rate of 13% during the forecast period. 

    Oncology drugs include a wide range of treatments, including targeted therapies, chemotherapy agents, immunotherapies, and hormone therapies, all developed to combat cancer.

    A Big problem…

    Conventional cancer therapies do not always work. 

    • They kill replicating cancer cells, but deep inside tumors are cells that develop resistance, called cancer stem cells. 
    • Can remain dormant for long periods. 
    • Migrate to other organs spreading the cancer.

    A Solution…

    PPCB’s lead candidate PRP represents a new advancement in the treatment of cancer by inducing cell differentiation, impairing angiogenesis, inhibiting cancer stem cell formation, and blocking the EMT process, known as differentiation therapy. This is an exciting anti-cancer stem cell therapy!

    The TOP 10 Reasons to Have PPCB on Your Radar:

    1. Developing its lead product, PRP, to treat early-stage cancer and pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer, based on genetic screening.
    2. Executive leadership with significant scientific, clinical and operational experience.
    3. PRP is a novel technology with a large-scale global potential that not only treats metastatic cancer but reduces the rate of recurrence. PRP offers a paradigm shift in the standard of care. No adverse events were observed from compassionate patient treatment.
    4. Few, or little treatment options exist for many aggressive tumor types which may become resistant over time, causing patient relapse. This gives the company a remarkable opportunity to address the global, unmet medical need to combat solid tumor recurrence and metastasis.
    5. Approximately 80% of cancers are from solid tumors, and metastasis is the main cause of patient death. Proenzyme therapy targets and eradicates cancer stem cells not killed by radiation or chemotherapy.
    6. Achieved Orphan Drug Designation from the FDA for treating pancreatic cancer.
    7. Building a robust patent portfolio around its scientific understanding of the effects of pro-enzymes in cancer, new formulations, new routes of administration, and potential new targets.
    8. 15 years of scientific research and clinical experience suggest PRP has the potential to convert cancerous cells back into normal cells.
    9. The Company has two lead assets, PRP and  Rec-PRP from its POP1 joint research and drug discovery program, with a mode of action that has broad market potential to target most common solid tumors.
    10. Maintains research partnerships with the University of Bath, University of Jaén, University of Granada, and the Foundation for Biosanitary Research of Andalusia Orients.

    Propanc Biopharma, Inc. (OTC: PPCB) Has a Novel Approach to Treating Metastatic Cancer that Could Turn the Company into Another Biotech Darling!

    Company Overview:

    Propanc Biopharma is a clinical-stage biopharmaceutical company developing new cancer treatments for solid tumors. Propanc has developed a formulation of anti-cancer compounds designed to control or prevent tumors from recurring and spreading throughout the body by using proenzymes, which are inactive enzyme precursors. 

    The company intends to target patients with limited therapeutic options for the treatment of solid tumors, initially pancreatic, ovarian, or colorectal tumors. 

    PPCB’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer!

    View the Company’s "Mechanism of Action" video on its anti-cancer lead product candidate, PRP

    Lead Candidate PRP

    PRP controls cancer cell migration, inhibits tumor blood vessel formation, and triggers the cell’s death.

    Metastasis occurs because a program inside the cell called the Epithelial-Mesenchymal Transition (EMT) is activated, which causes epithelial cancer cells to become invasive and stem cell-like, allowing these cancer cells to spread and metastasize. 

    The company’s lead product, PRP, is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from the bovine pancreas, administered by intravenous injection.

    • Mixture of 2 proenzymes from bovine pancreas.
    • Synergistic ratio of 1:6 inhibits growth of most tumor cells, in vitro.
    • Examples include ovarian and colorectal cancers.
    • Efficacy also shown in pancreatic, kidney, breast, brain, prostate, lung, liver, uterine and skin cancers.
    • Achieved Orphan Drug Designation from the FDA for treating pancreatic cancer.

    The Importance of Enzyme Therapy:

    Enzyme therapy allows us to fight cancer, using natural elements already found within our organism. Enzymes are natural proteins that stimulate and accelerate biological reactions in the body. The enzymes that are secreted by the exocrine pancreas are essential for the digestion of proteins and fats.

    More than one hundred years ago, Professor John Beard first proposed that pancreatic enzymes represent the body’s primary defense against cancer and would be useful as a cancer treatment. Since then, several scientists have endorsed Beard´s hypothesis with encouraging data from patient treatment.

    Encouraging Studies:

    Studies show the effects of Propanc’s PRP on reducing chemoresistance in pancreatic tumor cells.

    PPCB has announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy.

    The results were reported by the Company’s joint researcher, Mrs. Belén Toledo Cutillas, MSc, at the laboratory of Professor Macarena Perán, PhD, University of Jaén, Granada, Spain.

    Various methods, including apoptosis (programmed cell death) and viability analysis, live/dead assays, and RT-qPCR (real time quantification of gene expression) analyses confirmed PRP enhances the sensitivity of pancreatic tumor cells to standard chemotherapy treatment and decreases expression of genes related to chemoresistance. 

    It was also proven that a major pathway, TGF-β, responsible for tumorigenesis (production or formation of tumors) and metastasis (cancer spread), is involved with the observed effects by inhibiting this pathway after PRP treatment. 

    Similar analyses and an in vivo (in a living organism) study evaluating the effects on the tumor microenvironment confirmed transformational changes to the extracellular matrix components of the resistant tumors and according to Mrs. Cutillas, “seems to re-educate the malignant tumor cells by inducing apoptosis and reversing their malignant phenotype (cellular characteristics).

    “Results from the experiments conducted by Belen demonstrates the effects of PRP on reducing chemoresistance in pancreatic tumor cells, which is a significant issue among pancreatic adenocarcinoma (PDAC) patients, who have a poor 5-year survival rate of less than eight percent. We look forward to investigating the clinical effects in patients as we progress with future planned clinical trials, where an opportunity for a combinatorial therapeutic strategy may be uncovered to treat these resistant tumors.” - Dr Julian Kenyon, MD, MB, ChB, Propanc’s Chief Scientific Officer

    First-In-Human Study:

    PPCB will target the Peter Mac Cancer Center in Melbourne, Australia, as the site for the First-In-Human (FIH) study for PRP in patients with advaAnced solid tumors. 

    Initial discussion held previously with the Clinical Investigator confirmed the remaining development activities to be conducted by the Company prior to filing the clinical trial application for the FIH study. This includes the finished drug product manufacture and validation of the bioanalytical method to analyze the pharmacokinetics (movement of drug within the body) of PRP during the study.

    Significant Market Opportunity for Cancer Therapy:

    80% of all cancers are solid tumors and PPCB is initially targeting:

    • Pancreatic
    • Ovarian
    • Colorectal tumors

    Pancreatic cancer:

    When he revealed in an email from a hospital bed in 2004 that he had a rare form of pancreatic cancer, former Apple CEO Steve Jobs' health became a topic of intense interest and it shed a light on pancreatic cancer. Other celebrities who have succumbed to the disease include Alex Trebek, Ruth Bader Ginsburg, and Aretha Franklin. 

    Thousands of regular people have died from the painful disease and their families and friends have suffered with them.

    The American Cancer Society’s estimates for pancreatic cancer in the United States for 2023 are:

    • About 64,050 people (33,130 men and 30,920 women) will be diagnosed with pancreatic cancer.
    • About 50,550 people (26,620 men and 23,930 women) will die of pancreatic cancer.

    Just looking at these numbers shows that out of roughly 64,000 cases diagnosed, about 50,000 people will die. That’s a huge number. 

    Major players in the pancreatic cancer drugs market include Eli Lilly and Company, Pfizer, Novartis AG, Amgen, Celegene Corporation, and GlaxoSmithKline and Abbvie Inc. These are well-established companies with tremendous market caps.

    PPCB is an underfollowed company in the OTC market that is also leading the revolution in fighting pancreas cancer and other cancers with a novel approach!

    Colorectal tumors:

    Colorectal cancer is on the rise in an alarming trend. The diagnoses of colorectal (colon) cancer are on the rise in people under age 50. This led the U.S. Preventative Services Task Force to change its recommendations in May 2021 for colon cancer screenings to begin at age 45!

    Changes in the gut microbiome may be influencing the increasing rates of colorectal cancer in adults under 50. Studies have shown that diet, obesity, exercise, and some drugs (such as antibiotics) can all change the number and types of bacteria in our gut.

    Every 3 years, the American Cancer Society provides an update of CRC statistics based on incidence from population-based cancer registries and mortality from the National Center for Health Statistics. In 2023, approximately 153,020 individuals will be diagnosed with CRC and 52,550 will die from the disease, including 19,550 cases and 3750 deaths in individuals younger than 50 years.

    Ovarian cancer:

    Ovarian cancer is the sixth most common cancer in the world and one of the most aggressive reproductive cancers among women. Most ovarian cancers are diagnosed at late stages (stage 3 or 4) due to the typical absence of symptoms and lack of screening approaches.

    Late-stage diagnosis results in relatively high risks of recurrence and often poor prognosis. While the five-year survival rate for stage 1 ovarian cancer is over 80%, the corresponding survival rate for Stage 4 cancer is 20%. Worldwide, over 200,000 cases of ovarian cancer are diagnosed annually.

    A Competitive Advantage:

    PPCB provides a competitive advantage over other treatments available. Current drugs in the market offer, at most, a few months of extra life or tumor stabilization.

    The company’s long-term therapy based on a pancreatic proenzyme formulation prevents tumor recurrence and metastasis, the main cause of patient death from cancer.

    Lead product, PRP, has the potential to convert cancerous cells back to normal cell behavior!!

    In Summary….

    The growing demand for new cancer treatments can be attributed to a rapidly aging population and changing environmental factors in Western countries. The chances of developing cancer increase as a person gets older because more time has been available for mutations to accumulate.

    According to the World Health Organization, all cancers (excluding non-melanoma skin cancer) are expected to increase from 8.2 million deaths, in 2012, to more than 10 million deaths by 2020, exceeding 13 million annual deaths by 2030.

    Players in the oncology sector are thriving and Propanc Biopharma, Inc. (OTC: PPCB) may emerge as the next victor in this burgeoning arena. 2024 could be a breakout year for the company!

    "Despite facing significant global challenges in recent years as a micro-cap company, we face the future heading into the new financial year with growing optimism. We expect to enter clinical development stage with PRP, which management believes will identify a new therapeutic approach to the treatment and prevention of metastatic cancer, which remains the main cause of patient death for sufferers. PRP does not exhibit the same severe or even serious side effects compared to standard therapies – no hair loss, no nausea, no immune suppression – which is an important consideration for patients and their loved ones. We also expect to capitalize on the significant groundwork over the last 15 years, reflected in recent advancements, such as our growing IP portfolio, which now includes 76 patents filed in major, global jurisdictions.”

    James Nathanielsz, Propanc’s Chief Executive Officer

    PPCB’s lead product PRP has the potential to force cancer stem cells to become benign! This is groundbreaking science and may alter the landscape of solid tumor treatment forever!


    Learn More about Propanc Biopharma, Inc. by gaining access to the latest research report

    Download Report

    Contact us

    SmallCapsDaily, LLC
    1334 Northampton St, Easton, PA 18042




    SCD Media LLC (d/b/a “Smallcaps Daily”), hereinafter referred to as “Smallcaps Daily,” and their affiliates and control
    persons (the “Publisher”) are in the business of publishing favorable information and/or advertisements (the
    “Information”) about the securities of publicly traded companies (each an “Issuer” or collectively the “Issuers”) in
    exchange for compensation (the “Campaigns”). Persons receiving the Information are referred to as the “Recipients.”
    The person or entity paying the Publisher for the Campaign is referred to herein as the “Paying Party”. The Paying
    Party may be an Issuer, an affiliated or non-affiliate shareholder of an Issuer, or another person hired by the Issuer or
    an affiliate or non-affiliate shareholder of the Issuer. The nature and amount of compensation paid to the Publisher
    for the Campaign and creating and/or publishing the Information about each Issuer is set forth below under the
    heading captioned, “Compensation”.

    This website provides information about the stock market and other investments. This website does not provide
    investment advice and should not be used as a replacement for investment advice from a qualified professional. This
    website is for informational purposes only. The Author of this website is not a registered investment advisor and
    does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should
    seek the advice of a qualified securities professional before making any investment.
    Nothing on this website should be considered personalized financial advice. Any investments recommended herein
    should be made only after consulting with your personal investment advisor and only after performing your own
    research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.
    Smallcaps Daily, its managers, its employees, affiliates, and assigns (collectively the "Publisher") do not make any
    guarantee or warranty about the advice provided on this website or what is otherwise advertised above.

    Release of Liability: through use of this website, viewing or using you agree to hold Smallcaps Daily, its operators,
    owners, and employees harmless and to completely release them from any and all liability due to any and all loss
    (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The
    information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being
    accurate and does not purport to be a complete statement or summary of the available data. Smallcaps Daily
    encourages readers and investors to supplement the information in these reports with independent research and
    other professional advice. All information on featured companies is provided by the company profiled or is available
    from public sources and Smallcaps Daily makes no representations, warranties, or guarantees as to the accuracy or
    completeness of the disclosure by the profiled company. None of the materials or advertisements herein constitute
    offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any
    such company or other financial decisions should not be made based upon the information provided herein. Instead,
    Smallcaps Daily strongly urges you to conduct a complete and independent investigation of the respective
    companies and consideration of all pertinent risks. Smallcaps Daily’s full disclosure is to be read and fully understood
    before using Smallcaps Daily's website, or joining Smallcaps Daily's email or text list. From time to time, Smallcaps
    Daily will disseminate information about a company via website, email, sms, and other points of media. By viewing
    Smallcaps Daily's website and/or reading Smallcaps Daily's email or text newsletter you are agreeing to this ---->
    https://Smallcaps All potential percentage gains discussed in any communications are based
    on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising
    companies for monetary compensation.  
    If you have questions or concerns about a product you’ve seen in one of our emails, emails, text newsletters or SMS,
    we encourage you to reach out to that company directly.

    Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This
    communication is never to be used as the basis of making investment decisions and is for entertainment purposes
    only. At most, this communication should serve only as a starting point to do your own research and consult with a
    licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter
    is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned,
    operated, and edited by the owner of Smallcaps Daily. Any wording found in this e-mail or disclaimer referencing to “I”
    or “we” or “our” refers to Smallcaps Daily. Our business model is to be financially compensated to market and
    promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer,
    which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide
    investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment
    recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only
    invest what you can afford to lose. By using our service, you agree not to hold our site, its editors, owners, or staff
    liable for any damages, financial or otherwise, that may occur due to any action you may take based on the
    information contained within our newsletters or on our website. We do not advise any reader to take any specific
    action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads.
    Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains
    mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its
    owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time
    without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will
    list the information relevant to the stock and the number of shares here.

    In compliance with section 17(b) of the Securities Act Small Caps Daily is disclosing that we have been compensated
    a fee pursuant to an agreement between Smallcaps Daily and IA Media LLC (d/b/a/ “IA Media”) hereinafter referred to
    as IA Media. Please see IA Media’s disclosure page here. Small Caps Daily was hired by IA Media for a period
    beginning November 2023 and ending December 2023 to publicly disseminate information about Propanc
    Biopharma, Inc., via website, email, and SMS Small Caps Daily was paid up to twenty-five thousand usd via ACH.
    Readers are advised to review SEC periodic reports: forms 10Q 10K, form 8K, insider reports, forms 3, 4, 5 schedule
    13d. Smallcaps Daily is compliant with the CAN-SPAM Act of 2003. Smallcaps Daily does not offer investment advice
    or analysis, and Smallcaps Daily further urges you to consult your own independent tax, business, financial, and
    investment advisors. Investing in micro-cap, small-cap, and growth securities is highly speculative and carries an
    extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the
    speculative nature of the companies profiled. The private securities litigation reform act of 1995 provides investors a
    safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect
    to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events, or
    performance are not statements of historical fact but may be forward-looking statements. Forward-looking
    statements are based on expectations, estimates, and projections at the time the statements are made that involve a
    number of risks and uncertainties which could cause actual results or events to differ materially from those presently
    anticipated. Forward-looking statements in this action may be identified through the use of words such as projects,
    foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions &
    quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future
    results in preparing this publication. Smallcaps Daily has relied upon information supplied by its clients, as well as its
    clients’ publicly available information and press releases which it believes to be reliable; however, such reliability can
    not be guaranteed. Investors should not rely on the information contained on this website. Rather, investors should
    use the information contained in this website as a starting point for doing additional independent research on the
    featured companies. The advertisements in this website are believed to be reliable, however, Smallcaps Daily and its
    owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the
    completeness or accuracy of the information contained in any advertisement and for any omissions of material facts
    from such advertisement. Smallcaps Daily is not responsible for any claims made by the companies advertised
    herein, nor is Smallcaps Daily responsible for any other promotional firm, its program, or its structure. Smallcaps Daily
    is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission, or FINRA.

    Copyright © 2023 Smallcaps Daily. All rights reserved.

      Thanks for subscribing!
      Check your email for a confirmation message.